Enveric Biosciences has presented research highlighting the its lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. EB-003 is a neuropathogenic and non-hallucinogenic N, ...

$50,000 award will grant access to LabCentral's lab space, shared resources, and community to one early-stage biotech company working to treat or cure type 1 diabetes. As part of a first-of-its-kind ...

Congress recently introduced a bill that could expand access to therapeutic psychedelics that are designated as Breakthrough Therapies. These products are potentially useful in treating addiction, ...

Breakthrough T1D invites early-stage companies pursuing research relevant to Disease Modifying Therapies (DMT) and Cell Therapies (CT) research strategies to apply for the Breakthrough T1D Golden ...